Payment overview · 2025
General Payments
$87.75
4 reported records · 3 companies
Healthcare provider profile · identity verified
Stacy Hardy, MD
Allopathic & Osteopathic Physicians|Internal Medicine · MCALESTER, OK · NPI 1396708517
Verified facts
What the public records show
CMS Open Payments records show Stacy Hardy, MD received $87.75 in general payments during 2025 across 4 reported records.
Sumitomo Pharma America, Inc. accounted for 62.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gemtesa, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Nexium by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $54.38 | 62.0% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $18.44 | 21.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.93 | 17.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $87.75 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $54.38 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $18.44 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
35 | 12 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 411 | 102 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 395 | 68 |
| Levothyroxine Sodium | Levothyroxine Sodium | 380 | 103 |
| Lisinopril | Lisinopril | 306 | 88 |
| Gabapentin | Gabapentin | 288 | 72 |
| Atorvastatin Calcium | Atorvastatin Calcium | 276 | 90 |
| Omeprazole | Omeprazole | 254 | 72 |
| Furosemide | Furosemide | 234 | 77 |
| Tramadol Hcl | Tramadol Hcl | 220 | 40 |
| Citalopram Hbr | Citalopram Hydrobromide | 219 | 52 |
| Losartan Potassium | Losartan Potassium | 195 | 60 |
| Potassium Chloride | Potassium Chloride | 177 | 50 |
| Hydrochlorothiazide | Hydrochlorothiazide | 176 | 49 |
| Pantoprazole Sodium | Pantoprazole Sodium | 164 | 44 |
| Metformin Hcl | Metformin Hcl | 161 | 46 |
| Metoprolol Succinate | Metoprolol Succinate | 157 | 50 |
| Alprazolam | Alprazolam | 152 | 20 |
| Meloxicam | Meloxicam | 150 | 38 |
| Ozempic | Semaglutide | 149 | 23 |
| Eliquis | Apixaban | 142 | 33 |
| Montelukast Sodium | Montelukast Sodium | 133 | 43 |
| Trazodone Hcl | Trazodone Hcl | 125 | 31 |
| Metoprolol Tartrate | Metoprolol Tartrate | 122 | 36 |
| Buspirone Hcl | Buspirone Hcl | 118 | 29 |
| Azithromycin | Azithromycin | 115 | 81 |
| Carvedilol | Carvedilol | 114 | 38 |
| Simvastatin | Simvastatin | 109 | 34 |
| Glimepiride | Glimepiride | 106 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 101 | 35 |
| Sertraline Hcl | Sertraline Hcl | 98 | 25 |
| Estradiol | Estradiol | 90 | 34 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 89 | suppressed |
| Temazepam | Temazepam | 89 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 89 | 20 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 85 | 33 |
| Lorazepam | Lorazepam | 82 | 24 |
| Clonazepam | Clonazepam | 81 | 17 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 75 | 48 |
| Tizanidine Hcl | Tizanidine Hcl | 75 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 71 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 69 | 24 |
| Allopurinol | Allopurinol | 66 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 66 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 65 | 26 |
| Metformin Hcl Er | Metformin Hcl | 65 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 60 | 19 |
| Ezetimibe | Ezetimibe | 60 | 17 |
| Pregabalin | Pregabalin | 58 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 57 | 15 |
| Fluconazole | Fluconazole | 56 | 33 |
| Celecoxib | Celecoxib | 52 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 52 | 14 |
| Diazepam | Diazepam | 51 | 14 |
| Prednisone | Prednisone | 51 | 25 |
| Alendronate Sodium | Alendronate Sodium | 47 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 43 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 43 | 31 |
| Amitriptyline Hcl | Amitriptyline Hcl | 40 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 40 | 32 |
| Hydralazine Hcl | Hydralazine Hcl | 36 | 12 |
| Memantine Hcl | Memantine Hcl | 36 | suppressed |
| Methylprednisolone | Methylprednisolone | 36 | 32 |
| Tamsulosin Hcl | Tamsulosin Hcl | 36 | 17 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 35 | 11 |
| Synthroid | Levothyroxine Sodium | 35 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 34 | suppressed |
| Spironolactone | Spironolactone | 33 | 11 |
| Xarelto | Rivaroxaban | 32 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 31 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 30 | suppressed |
| Ibuprofen | Ibuprofen | 30 | suppressed |
| Primidone | Primidone | 30 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 28 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 28 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 27 | suppressed |
| Sucralfate | Sucralfate | 27 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 27 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 26 | suppressed |
| Myrbetriq | Mirabegron | 26 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 25 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 25 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 25 | suppressed |
| Bupropion Xl | Bupropion Hcl | 24 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 24 | suppressed |
| Levofloxacin | Levofloxacin | 24 | 17 |
| Mupirocin | Mupirocin | 24 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 24 | 13 |
| Atenolol | Atenolol | 23 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 23 | suppressed |
| Fentanyl | Fentanyl | 23 | suppressed |
| Glipizide | Glipizide | 23 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | suppressed |
| Torsemide | Torsemide | 23 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 22 | suppressed |
| Cephalexin | Cephalexin | 22 | 16 |
| Jardiance | Empagliflozin | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Verapamil Er | Verapamil Hcl | 22 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 21 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 21 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 20 | suppressed |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Risperidone | Risperidone | 20 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 20 | suppressed |
| Baclofen | Baclofen | 19 | suppressed |
| Lansoprazole | Lansoprazole | 19 | suppressed |
| Amoxicillin | Amoxicillin | 18 | 16 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 18 | suppressed |
| Famotidine | Famotidine | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Methadone Hcl | Methadone Hcl | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Januvia | Sitagliptin Phosphate | 17 | suppressed |
| Gemtesa | Vibegron | 16 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | suppressed |
| Mirtazapine | Mirtazapine | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 15 | suppressed |
| Constulose | Lactulose | 14 | suppressed |
| Latanoprost | Latanoprost | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 14 | suppressed |
| Mounjaro | Tirzepatide | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | suppressed |
| Dexamethasone | Dexamethasone | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | suppressed |
| Nexium | Esomeprazole Magnesium | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Vraylar | Cariprazine Hcl | 12 | suppressed |
| Alprazolam Xr | Alprazolam | 11 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 11 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Famciclovir | Famciclovir | 11 | suppressed |
| Finasteride | Finasteride | 11 | suppressed |
| Glyburide | Glyburide | 11 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Pindolol | Pindolol | 11 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $87.75 · 4 records | Sumitomo Pharma America, Inc. | GEMTESA, VRAYLAR | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gemtesa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error